Prazepamの代謝に関する研究(第1報)Prazepamのラットにおける体内動態
スポンサーリンク
概要
- 論文の詳細を見る
The metabolic fate of Prazepam (PZ), (7-chloro-1-cyclopropylmethyl-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one) was studied in rats. After oral or intravenous administration of 5-^<14>C-PZ, the radioactivity was detected in various tissues, indicating extensive uptake of this compound. A higher level of the radioactivity was seen in the liver, small intestine, stomach, adrenal, and kidneys. After oral administration, the radioactivity level in the brain was nearly comparable to that in the blood. In the case of intravenous administration, however, the level in the brain was several times higher than that in the blood. In each route of administration, fecal excretion mostly resulting from biliary excretion was the major elimination route of this drug. A major metabolite in the urine was 4'-hydroxydesalkylprazepam (4'-HDPZ) sulfate which was also found in the bile. Other major metabolites in the bile were 3-hydroxyprazepam (HPZ) glucuronide and metabolite A which was present as free and conjugated forms. Most of the biliary metabolites were found in the feces as a free form with the unchanged drug. Metabolite A was isolated from the bile and identified as 3'-hydroxydesalkylprazepam (3'-HDPZ). Major metabolites in the plasma, liver, and kidneys were desalkylprazepam (DPZ), oxazepam (OX), 4'-HDPZ, and its sulfate. In the brain, DPZ and OX were the major metabolites, but a small amount of the unchanged drug and HPZ was also detected. These results suggest that the main reactions in the PZ metabolism are C_3-hydroxylation to HPZ and N-dealkylation to DPZ followed by aromatic hydroxylation to 3'- and 4'-HDPZ or C_3-hydroxylation to OX. These metabolic patterns were not altered after a repeated administration. The relationship between the pharmacological activity and metabolism of this drug is also discussed.
- 社団法人日本薬学会の論文
- 1978-06-25
著者
-
玉木 太郎
興和株式会社東京研究所
-
玉木 太郎
興和
-
玉木 太郎
興和東京研究所
-
甲 重雄
興和株式会社東京研究所
-
石浜 洋
興和株式会社東京研究所
-
木全 秀樹
興和株式会社東京研究所
-
米光 正博
興和株式会社東京研究所
-
木全 秀樹
興和株式会社 東京創薬研究所
関連論文
- HMG-CoA還元酵素阻害剤によるapolipoproteinB_100分泌の抑制
- Prazepamの代謝に関する研究(第4報)Prazepamのサルにおける体内動態
- Prazepamの代謝に関する研究(第1報)Prazepamのラットにおける体内動態
- Paeonolの生合成
- Prazepamの代謝に関する研究(第3報)PrazepamのCyclopropylmethyl基のラットにおける体内動態
- Prazepamの代謝に関する研究(第2報)Prazepam, DiazepamおよびDesalkylprazepamのラット肝ミクロゾームによる代謝
- 組織因子誘発ラット DIC モデルに対するグリコサミノグリカン鎖付加型可溶性ヒトトロンボモジュリン (GAG-UTM) の臓器内血栓形成抑制作用
- オートラジオグラフィによる骨粗鬆症モデルラットの骨密度測定
- Fibrinolytic Effect of Tissue Plasminogen Activator on Cerebral Embolism in Stroke-Prone Spontaneously Hypertensive Rats
- マイクロプレート-ラジオルミノグラフィによる放射能の測定, マイクロプレート乾燥機の開発
- Prazepam, DesalkylprazepamおよびDiazepamとヒト血清アルブミンとの結合
- 14C標識Prazepamの合成